20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
(AIDX)
Company Research
Source: GlobeNewswire
Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”), 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. (“ROKIT”), a global innovator in chronic disease prediction and regenerative health technologies. Under the agreement, 20/20 will integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into the 20/20 Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools. Under the agreement, ROKIT agreed to reimburse 20/20 for one-third of mutually agreed sales and marketing expenses in
Show less
Read more
Impact Snapshot
Event Time:
AIDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AIDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AIDX alerts
High impacting news events
Weekly update
A roundup of the hottest topics
AIDX
News
- 20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational ProgressGlobeNewswire
- Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest ™ Multi-Cancer Early Detection Blood Test [Yahoo! Finance]Yahoo! Finance
- Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood TestGlobeNewswire
- 20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program [Yahoo! Finance]Yahoo! Finance
- 20/20 Biolabs (AIDX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AIDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "hold".MarketBeat
AIDX
Sec Filings
- 3/31/26 - Form 10-K
- 3/10/26 - Form SCHEDULE
- 3/10/26 - Form SCHEDULE
- AIDX's page on the SEC website